logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12453781 B1

PDFFull Text
Date of Patent:
Oct. 28, 2025

Filed:

Oct. 28, 2019

Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate

Applicant:

Genmab A/s, Copenhagen V, DK;

Inventors:

Reshma Abdulla Rangwala, Philadelphia, PA (US);

Sandra Verploegen, Nieuwegein, NL;

Esther C. W. Breij, Driebergen, NL;

Oyewale O. Abidoye, Bellevue, WA (US);

Leonardo Viana Nicacio, Redmond, WA (US);

Assignee:

Genmab A/S, Valby, DK;

Attorney:

MORRISON & FOERSTER LLP

Primary Examiner:

Michail A Belyavskyi

Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); C07K 16/36 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6869 (2017.08); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/36 (2013.01); A61K 2039/507 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01);
Abstract

The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.

Find Patent Forward Citations

Rangwala, Reshma. (2025). Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate (U.S. Patent No. 12453781). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12453781

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…